Skip to Content

MainStay Balanced C MBACX

Medalist Rating as of | See New York Life Investment Hub
  • NAV / 1-Day Return 28.98  /  −0.38 %
  • Total Assets 445.5 Mil
  • Adj. Expense Ratio
    2.080%
  • Expense Ratio 2.080%
  • Distribution Fee Level High
  • Share Class Type Level Load
  • Category Moderate Allocation
  • Investment Style Large Value
  • Credit Quality / Interest Rate Sensitivity High/Limited
  • Status Open
  • TTM Yield 1.07%
  • Turnover 313%

USD | NAV as of Apr 16, 2024 | 1-Day Return as of Apr 16, 2024, 10:03 PM GMT+0

Morningstar’s Analysis MBACX

Will MBACX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

MainStay Balanced C's Average People Pillar and Process Pillar ratings are n't enough to prevent other weaknesses from sending this strategy to a Morningstar Medalist Rating of Negative.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the most expensive quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings MBACX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

United States Treasury Notes 4.25%

6.60 29.9 Mil
Government

United States Treasury Notes 4.125%

4.40 19.9 Mil
Government

iShares Intermediate Govt/Crdt Bd ETF

4.18 18.9 Mil

United States Treasury Notes 4%

3.16 14.3 Mil
Government

United States Treasury Notes 4%

2.29 10.4 Mil
Government

JPMorgan Chase & Co

2.26 10.2 Mil
Financial Services

Us Dollar

2.25 10.2 Mil
Cash and Equivalents

Vanguard Russell 1000 Value ETF

2.05 9.3 Mil

Johnson & Johnson

1.76 8.0 Mil
Healthcare

Merck & Co Inc

1.68 7.6 Mil
Healthcare